Placeholder Banner

BIO's Dr. McMurry-Heath Applauds Nasdaq's Proposal on Mandatory Diversity for Listed Companies

December 2, 2020
Media Contact
Theresa Brady
202.962.9235

Washington, DC (December 2, 2020) - Dr. Michelle McMurry-Heath, President and CEO of the Biotechnology Innovation Organization (BIO), issued the following statement regarding Nasdaq's filing with the Securities and Exchange Commission seeking mandatory board diversity for listed companies:

“The Actions taken by NASDAQ are bold, long overdue and will serve as inspiration for Boardrooms across the nation. The biotech industry has been, and remains committed to promoting inclusivity, by accelerating gender, racial, ethnic and LGBTQ representation. In fact, many of our companies already exceed some of these requirements while we understand more work needs to be done. The goal of inclusion does more than just 'level the playing field' it makes good business sense and helps organizations grow and prosper. BIO is very supportive of Nasdaq’s proposal and looks forward to assisting with the implementation of this initiative in our sector.”

###

 

Discover More
President-elect Joe Biden announced on Friday a plan to make the White House Office of Science and Technology Policy a Cabinet-level agency. Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), made the…
Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on BIO's political contributions:   "As of today BIO will be pausing our political giving so we can…
Dr. Michelle McMurry-Heath, President and CEO of the Biotechnology Innovation Organization, made the following comments in response to today's violence at the United States Capitol: "Today we watched in horror as angry and unruly mobs attacked…